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Abstract 
Parkinson’s disease is highly heterogeneous in early clinical features and later outcomes.   
This fact makes classifying subgroups of PD relevant to clinical research and practice, 
particularly if they are prognostically relevant.  Subgroups have been defined both on the 
basis of motor and non-motor features, and subgroups have been determined either 
empirically, based on clinical observation, or using data-driven analytic techniques.  
Previous studies have examined both the overall number and the nature of non-motor 
symptoms and signs in tremor dominant compared with non-tremor dominant subtypes 
and longitudinal studies identify non-motor symptoms as important markers of prognosis and 
important defining features of PD subtypes .  Autonomic features seem to preferentially affect 
individuals with non-tremor dominant PD-subtype early in the disease. Later in the disease 
cognitive disturbance distinguishes this phenotype.  Pathological and neuroimaging studies 
provide substantial evidence for fundamental biological differences between tremor 
dominant and postural instability gait disorder (PIGD)/akinetic-rigid subtypes.  Biomarker 
studies point towards non-tremor dominant PD as representing a more advanced and 
diffuse neurodegeneration than tremor dominant PD, encompassing dopaminergic and 
non-dopaminergic as well as synuclein and non-synuclein (Abeta) pathologies.  This aligns 
with clinical studies that find a higher burden of non-motor symptoms in non-tremor 
dominant PD.  The mounting evidence for the relevance of non-motor features in PD 
subtypes behooves us to begin to investigate the biological underpinnings of subtypes 
defined by both motor and non-motor features.  This may be challenging, as PD subtypes 
are unlikely to be distinct, non-overlapping entities but are more likely to represent typical 
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phenotypes within a multidimensional spectrum resulting from variable contributions of a 
number of simultaneous pathological processes. 
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Introduction 
 
 
12, 345, 6 
Clinically, Parkinson’s disease (PD) is highly heterogeneous.  Identifying the clustering or 
co-occurence of clinical features in groups of patients forms the basis of subtyping.  
Subtypes of a disease are relevant if they predict outcome or response to treatment.     .  
Subtypes that do so should inform clinical research in that heterogeneity that is 
unaccounted for in clinical trials or etiological studies can obscure associations when 
different subtypes vary in their associations with an outcome measure of interest.  
Subtyping may also help us to understand the biology of the disease.  Thus, in a highly 
heterogeneous disease such as PD, subtyping is a useful strategy to guide research and 
ultimately clinical practice as well.  7  
 
Many efforts to define subtypes have been undertaken.  Subtypes can be subdivided into 
those derived empirically, from clinical observation   and a priori hypotheses as to how 
features of the disease are related to one another, or they may be derived without any such 
assumptions using a data-driven approach that divides patients into groups based on the 
co-occurrence of features included in the analysis (Figure 1)  
 
Empirical subtyping systems include dividing PD into age at onset categories, major motor 
phenotypes, patterns of cognitive impairment and other NMS as recently described6.  
Subtypes based on motor features are most commonly used.  Two main strategies of 
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empirical motor subtyping have been used.  One divides patients into either tremor 
dominant, postural instability gait disorder or intermediate phenotypes8 and the other 
divides patients into tremor dominant, akinetic/rigid and mixed phenotypes.9  The latter 
uses a broader array of non-tremor features to classify patients and different algorithms 
have been proposed.  Cognitive subtypes describe which and how many cognitive domains 
are affected,10 or whether predominantly frontal or posteriorly mediated cognitive 
functions are impaired.  The ‘posterior’ subtype has been proposed to have a worse 
prognosis.11  The approach taken by the recently published clinical NMS subtyping in PD is 
based on specific NMS dominant clinical phenotypes in largely untreated drug naïve as well 
as early treated PD cohorts.12  A description of these published phenotypic groups are 
shown in Table 1. 
 
Non-motor manifestations of PD are prominent and disabling aspects of the condition and 
we now understand that many of them precede the motor features of the disease.1  Indeed, 
pathological staging systems for PD describe the progression of the synucleinopathy as 
beginning in the lower brainstem and/or olfactory bulb,2, 3 areas which mediate a number 
of non-motor and non-dopaminergic functions.  Furthermore, it has been suggested that PD 
may begin peripherally in the gastrointestinal tract where synuclein deposition has been 
identified prior to the onset of parkinsonism.13  There is understandably great interest in 
understanding whether or not clinical features mediated by this early pathological 
involvement can be prognostically relevant.  Indeed specific clinical descriptions of Non-
Motor Symptom (NMS) dominant phenotypes, particularly in the untreated PD model , 
suggesting a link with the heterogeneity of the initiating neuropathological processes are 
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being increasingly described.4  The broad clinical phenotypes also reflect the underpinning 
convergence of deficits in multiple transmitter systems and pathways, including the cholinergic, 
noradrenergic, and serotonergic systems that occurs in PD.5, 6 
 
 
In NMS dominant phenotypes, unlike typical PD, specific NMS such as cognitive 
impairment, depression, anxiety or dysautonomia dominate with variable overall NMS 
burden and motor symptoms. These NMS dominated subtypes described in Table 1 broadly 
conform to the emerging evidence of differential pathways of neuronal degeneration and 
Lewy body pathology in the central nervous system as proposed by several authors.( 
Figure 2) and spread of pathology as proposed by Beach et al (2009)  and Braak et al 
(2003).2, 3, 14, 15 NMS subtype patterns reflect phenotypes driven largely by dominant limbic, 
brainstem or cognitive involvement even at a very early motor stage of PD . In some PD 
phenotypes such as those with dominant dysautonomia or depression, there is evidence of 
specific biochemical disturbances (e.g adrenergic).16( Fig 2)  
 
 
It is however important to note that PD is neither solely motor or non-motor, however, and 
naturally attempts to describe subtypes incorporating both aspects have been undertaken.    
Data-driven cluster analyses have led the way considering both motor and non-motor 
features for PD subtypes.  Numerous cluster analyses have been published considering a 
wide variety of symptoms and signs.  The results are heterogeneous, related to differences 
in variables entered into these analyses and the number of clusters sought, but data-driven 
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analyses have described subtypes that separate from each other most commonly  on age at 
onset, or rate of progression, less commonly ‘tremor dominance,’ psychopathology, 
cognitive impairment or the presence or absence of motor complications.17-25 When 
akinetic-rigid features and tremor are included in cluster analyses the emerging clusters 
have confirmed these aspects as defining features.23   The relationship between non-motor 
symptoms and the empirical motor subtypes has also been explored by many different 
groups.  We will summarize the current state of knowledge regarding non-motor 
symptoms in both empirical motor subtypes and data-driven classifications.  First, we will 
consider the spectrum of non-motor features and why they may be particularly important 
in the evolution of PD. 
 
The spectrum and relevance of non-motor features in PD 
NMS are now recognised to be integral to the concept of Parkinson’s disease (PD) and 
define the pre-motor stage while being variably present from onset of motor disease 
through to the endof the disease.26  
 
Clinically, NMS comprise a range of clinical signs and symptoms resulting from multiple 
neurotransmitter deficiencies and differential rates of neurodegeneration within the 
central and the peripheral nervous system as well as the gut.27-29 The range and nature of 
NMS of PD are wide and vary from cognitive and neuropsychiatric to sleep problems and 
dysautonomia either occurring isolation as the dominantfeature or in combination.27 Motor 
aspects of PD such as falls may also be intricately linked to specific NMS of PD such as 
cognition.30 Furthermore, some genetic variants of PD are thought to express specific NMS 
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while the clinical picture can be complicated by medication induced NMS such as impulse 
control disorders or dopamine agonist withdrawal syndromes.31 
While a single dominant NMS such as apathy, pain or depression can have a major 
detrimental effect on patient and carer health related quality of life (HrQOl), recent studies 
indicate that in others the overall burden of  a range of NMS that occur in PD could  also be 
a key determinant of HrQol. 32, 33 The grading of the burden of NMS is now possible using 
validated MDS endorsed tools such as the NMS scale or questionnaire combining 
assessment with motor scores.34  Thus, modern management of PD needs to take into 
account the heterogeneity and the burden of NMS in relation to outcome measures. 
 
 
Non-motor features in empirical motor subtypes 
 
Previous studies have examined both the overall number of non-motor symptoms and 
signs and the nature of non-motor symptoms and signs in tremor dominant compared with 
non-tremor dominant subtypes.  At least three studies have explored this issue in newly 
diagnosed patients.  Khoo et al.35 found a greater number of non-motor symptoms 
associated with the PIGD phenotype among 159 newly diagnosed non-demented PD 
patients.  When individual non-motor symptoms were examined, however, only sialorrhea 
was significantly more common in the PIGD subtype after Bonferroni correction.  
Constipation, autonomic and sensory symptoms were found to be more common in the 
non-tremor dominant subtype by Müller et al.36    In contrast, Pont-Sunyer et al. did not find 
a higher overall burden of non-motor symptoms in the akinetic-rigid phenotype (compared 
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with tremor-dominant individuals) within an incident PD cohort.37  After adjustment for 
age and gender only constipation was significantly more common in the akinetic-rigid 
phenotype.   
 
Using a putatively more sensitive approach, Herman et al. examined non-motor features 
distinguishing tremor dominant and PIGD subtypes.38  They eliminated from their 
comparison individuals who had tremor/pigd ratios that fell close to the indeterminate 
range – thus they contrasted extreme cases.  Using this approach they found that the PIGD 
group reported a larger number of non-motor symptoms on the Non-Motor Symptoms 
Questionnaire (NMS-Quest) and higher scores on the Scales for Outcomes in Parkinson’s 
Autonomic (SCOPA-AUT) scale.  They did not find differences in their cognitive 
performance, depression scores, olfactory identification or sleep quality.  Taken together, 
autonomic features seem to be a common feature preferentially affecting individuals with 
non-tremor dominant PD-subtype, early in the disease. 
 
Later in the disease, a different picture emerges, dominated by differences in the risk of 
cognitive impairment.  Rajput et al. classified 166 individuals from a pathologically 
confirmed cohort as tremor dominant, mixed or akinetic-rigid subtype according to the 
predominant subtype over the entire course of the disease. 39  They found a higher 
cumulative incidence of dementia in the akinetic-rigid subtype of PD than either 
intermediate or tremor-dominant subtypes.  Although there was no difference in survival, 
progression to Hoehn and Yahr stage 4 was faster in the akinetic-rigid subtype.  A higher 
risk of cognitive dysfunction in the akinetic-rigid subtype has also been found by others.23, 
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40  In cross sectional cohorts of variable disease duration affective symptoms23 and 
olfactory dysfunction have also been shown to be more common in non-tremor dominant 
patients.41   
 
Interpretation of studies is more straightforward when cohorts are studied at a uniform 
disease duration or longitudinally from the time of diagnosis.  Many studies, however, have  
considered individuals at various durations of disease, or even incorporated measurements 
taken from individuals at various time points throughout their disease.   In general 
differences have been found with all approaches.(Table 2) 
 
 
Whether early or late in the disease non-tremor dominant subtypes have consistently been 
shown to have a broader array of non-motor symptoms.  Early, autonomic features may 
predominate and later cognitive impairment is the most common non-motor issue. 
 
 
 
Biomarkers distinguishing empirical motor subtypes: pathological, imaging and biochemical 
evidence 
 
Clues to the biological basis of the clinical differences discussed above come from a number of 
biomarker and neuroimaging studies.  Together, this literature provides substantial evidence for 
fundamental biological differences between tremor dominant and PIGD/akinetic-rigid subtypes.    
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For example, a small pathological study of brains of individuals with PD showed the lowest 
pallidal dopamine levels in individuals classified as having the akinetic-rigid subtype and they 
identified a distinct pattern of pallidal dopamine loss between the subtypes.42  Disease duration 
varied widely across the individuals studied however, and was not reported by subtype so it is 
difficult to know whether or not the dopaminergic loss was related to the subtype per se or the 
more advanced disease process in these individuals.  Patients who have minimal manifestations 
of PD other than tremor for prolonged periods (benign tremulous PD) have been shown to have 
less nigral cell loss than other forms of PD matched for age and disease duration at death.43  
Functional neuroimaging studies also suggest lower striatal dopaminergic and glucose 
metabolism in akinetic-rigid patients.44  During a grip task, functional MRI also revealed reduced 
activation of the prefrontal cortex and globus pallidus of patients with nontremor-dominant PD 
compared with both patients with tremor-dominant PD and healthy controls.45  In addition, a 
tremor-specific metabolic network has been identified by FDG PET scanning, indicating that 
parkinsonian tremor is mediated at least in part by a distinct metabolic network involving 
primarily cerebello-thalamo-cortical pathways.46 The origin of this network abnormality is not 
well understood however; there is evidence that basal ganglia dopamine depletion drives the 
cerebello-thalamo-cortical abnormality.47  This would seem at odds with the view that akinetic-
rigid subtype has more severe pallidal dopamine depletion, suggesting a complex relationship 
between the cardinal manifestations of PD and basal ganglia dopamine depletion.  Basal ganglia 
iron load as measured by magnetic resonance imaging has also been investigated as a potential 
distinguishing feature of the motor subtypes with conflicting results.48, 49    
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PIGD symptoms respond poorly to dopaminergic therapy and are thought to be mediated by non-
dopaminergic mechanisms.  It follows to wonder if other non-dopaminergic and non-motor 
features are more common in this subtype.  Biomarker evidence for non-dopaminergic/non-
motor differences between tremor dominant and PIGD/akinetic-rigid phenotypes includes that 
from CSF studies and cardiac 123I-metaiodobenzylguanidine (MIBG) scanning.   
 
Schiess et al. examined cerebrospinal fluid neurotransmitter levels in tremor dominant, akinetic-
rigid and mixed groups.  They found that 5-hydroxyindolacetic acid and 5-hydroxytrypophan 
levels were lowest in the akinetic-rigid group while glutamate levels were highest.   The authors 
propose that the low levels of 5-HIAA were consistent with higher rates of depression and 
cognitive dysfunction in the akinetic-rigid subtype9 and overall indicating a more diffuse 
neurodegeneration encompassing non-dopaminergic systems.   
 
On the basis of several lines of evidence linking PIGD phenotype to cognitive impairment and 
linking cognitive impairment in PD to altered CSF amyloid50or amyloid deposition,15, 51 Alves et 
al. investigated CSF amyloid in PD motor phenotypes.52  PD patients with the PIGD phenotype 
had significant alterations in several Abeta species, including those representing amyloid 
aggregation and deposition (Abeta42) and metabolism(Abeta38 and Abeta40), raising the 
possibility that amyloid pathology may underlie PIGD symptoms and that this may be mediated 
by alterations in amyloid beta metabolism. CSF Abeta markers correlated with PIGD scores 
independent of age, MRI white matter hyperintensities and cognition.   
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Several studies have examined the relationship between motor phenotype and cardiac 123I-MIBG 
uptake, in order to assess the integrity of the noradrenergic cardiac presynaptic sympathetic 
system, known to degenerate in PD.  When groups have been comparable with respect to disease 
duration, 123I-MIBG uptake has been found to be lower in the akinetic-rigid or postural 
instability gait disorder subgroups, indicative of greater cardiac sympathetic denervation.53, 54 
  
Taken together, biomarker studies of tremor dominant vs non-tremor dominant PD point 
towards non-tremor dominant PD as representing a more advanced and diffuse 
neurodegeneration than tremor dominant PD, encompassing dopaminergic and non-
dopaminergic as well as synuclein and non-synuclein (Abeta) pathologies.  This aligns with 
clinical studies that find a higher burden of non-motor symptoms in non-tremor dominant 
PD.  The interpretation of this is not straightforward, however, in part because it is unclear 
whether or not tremor dominant or non-tremor dominance is a trait marking a 
fundamental distinction that endures throughout the course of PD or, alternatively, if it 
marks a state that may change.  The latter is supported by the observation that many 
patients who begin with tremor dominant PD switch over time to PIGD or akinetic-rigid 
PD.55   
 
Non-motor features in data-driven classifications 
 
Associations between non-motor features and the TD/PIGD phenotypes support the 
relevance of the motor subtypes in characterizing PD.  On the other hand, if non-motor 
features do not associate with the motor phenotype then it argues that by basing our 
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classifications of PD patients solely on the motor phenotype we may be missing important 
heterogeneity.  Liu et al examined the relationship between cluster assignments based on a 
data-driven approach incorporating motor and non-motor features (including mood, 
cognition, sleep quality, constipation and fatigue) in 138 patients with relatively early PD.21  
They found that the clusters emerging from their analysis did not bear a strong 
relationship to the empirical motor subtype of the patients.  This suggests that the addition 
of non-motor features in defining subtypes may be important.  Indeed, previous data-
driven analyses have largely found that both motor and non-motor features constitute 
defining characteristics of the subtypes that emerge.19-24, 56, 57 
 
With the improvement in our knowledge of the spectrum of non-motor features of PD, 
recent data-driven cluster analyses have investigated an expanded array of non-motor 
features and their contribution to PD subtypes.  The use of comprehensive instruments to 
elicit non-motor features such as the NMSQuest58 have facilitated this process.  
Importantly, recent studies have suggested that specific non-motor and non-dopaminergic 
symptoms may be particularly informative from a prognostic perspective.  Erro et al. 
investigated the clustering of motor and non-motor features in a cohort of early, untreated 
PD patients.59  They identified four clusters which they described as benign motor, benign 
mixed motor non-motor, non-motor dominant and motor dominant.  In both of the clusters 
involving prominent non-motor features they identified a non-motor domain that was 
particularly affected.  In the benign motor/non-motor group this was sexual symptoms and 
in the non-motor dominant group this was urinary symptoms.  A longitudinal study 
assessing non-motor predictors of time to levodopa requirement found urinary symptoms 
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to have the greatest predictive power of a short time to levodopa.60  Urinary symptoms 
were also associated with a greater burden of motor and non-motor symptoms both at 
baseline and follow-up.  Thus both studies suggest that among early non-motor symptoms 
urinary dysfunction may suggest a more malignant course.   
 
REM sleep behavior disorder (RBD) is another non-motor feature that has been suggested 
to have prognostic value.  In cross-sectional analyses, RBD in PD has been associated with 
older age, male gender, orthostatic drop in blood pressure and orthostatic symptoms, non-
tremor dominant motor phenotype, falls and depression.61 Others have found that patients 
with RBD have lower cardiac 123I MIBG uptake (presumably on the basis of premotor PD or 
diffuse Lewy body disease) even than individuals with early PD, indicative of early and 
more severe cardiac sympathetic dysfunction in those with RBD.62  Further, RBD has also 
been defined as a cardinal feature of PD subtypes.  Fereshtehnejad et al measured a 
comprehensive array of motor and non-motor features in PD patients including motor severity, 
motor complications, motor subtypes, quantitative motor tests, autonomic and psychiatric 
manifestations, olfaction, color vision, sleep parameters, and cognition.63  The most 
discriminating baseline features between the three emerging clusters were mild cognitive 
impairment, orthostatic hypotension, and RBD.  Upon follow-up, this cluster had more rapid 
progression of cognitive, motor and other non-motor domains.  With respect to the prognostic 
value of RBD and the aforementioned urinary dysfunction it is notable that both are features of 
multiple system atrophy, a synucleinopathy known to be more quickly progressive and often 
misdiagnosed as PD early in its course.  Whether or not these prognostic associations are related 
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to such misdiagnosis can only be revealed by longitudinal follow-up and/or pathological 
examination.    
 
De Lau and colleagues assessed the relationship between subtypes and survival in a longitudinal 
study of over 400 PD patients and found the shortest survival in patients that had previously been 
classified into clusters characterized by the most non-motor and non-dopaminergic features 
(namely postural instability/gait disturbance, cognitive impairment, autonomic dysfunction, 
depression, and psychosis).56  These studies identify non-motor symptoms as important markers 
of prognosis and important defining features of PD subtypes.   
 
Conclusions and Next Steps  
 
To date, motor subtyping has dominated the landscape of biomarker research, possibly 
because its unidimensional nature and easily measured components make it more easily 
applied.  Undeniably, the evidence suggests that there are important biological differences 
between the tremor-dominant and PIGD subtypes.  However the mounting evidence for the 
relevance of non-motor features in PD subtypes behooves us to begin to investigate the 
biological underpinnings of subtypes defined by both motor and non-motor features.  The 
current descriptions of specific NMS dominant phenotypes in untreated cohorts of PD and 
neuropathological heterogeneity of the disease process in PD further support the idea of 
non motor subtyping. This may be challenging, as PD subtypes are unlikely to be distinct, 
non-overlapping entities but are more likely to represent typical phenotypes within a 
17 
 
multidimensional spectrum resulting from variable contributions of a number of 
simultaneous pathological processes.  
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Legend to Figure 1:  Approaches to clinical subtyping in Parkinson’s disease.   Subtyping 
approaches can be divided into those that are empirically derived, from clinical 
observation, and data-driven based on co-occurrence of clinical features with no a priori 
hypothesis as to the way clinical features will cluster together.    
 
Legend to Figure 2:  Possible routes of spread of pathology in PD as described from 
pathophysiological studies and consequent phenotypic expression and non motor 
subtypes. RBD = rapid eye movement behaviour disorder, EDS = excessive daytime 
sleepiness, MCI = mild cognitive impairment. In some subtypes specific neurochemical 
deficits such as adrenergic, serotonergic, opioidergic and cholinergic pathways are 
preferentially involved sometimes greater than dopaminergic involvement.   
   = overlap between the phenotypes are possible. 
Blue areas in cognitive phenotype diagram indicate frontal and parietal involvement with 
underpinning cholinergic dysfunction. 
Fig adapted from Sauerbier et al.6. 
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Table 1 Clinical description of NMS dominant phenotypic variants in well characterized cohorts 
of PD (untreated and treated) as described in literature 
(Adapted from Sauerbier et al. 2015) 
 
Non-motor domain Defining features of subtype Ancillary features 
Cognitive30, 64, 65 Early and dominant cognitive 
dysfunction 
-Older age (≥ 72 years)                          
-Non-tremor dominant motor 
phenotype associated with falls 
-Poor semantic fluency score 
(<20) 
-Lower pentagon copying score 
(0<1<2) 
-Microtubule-associated protein 
tau (MAPT) H1/H1 genotype 
possibly a biomarker 
 
Neuropsychiatric Anxiety/depression:66, 67 
 
 
 A. Anxious-depressed  
 B. Depressed -Postural instability gait 
disturbance 
 C. Anxious -Younger age 
Marked motor fluctuations 
 Apathetic68 -Relatively severe motor 
symptoms (out of proportion 
to disease duration) 
-Concomitant depression 
-Lower cognitive status 
-Fatigue 
20 
 
-Good response to 
dopaminergic drugs 
 
Sleep REM sleep behavior disorder61 -Symmetric disease onset 
-Increased periods of freezing  
-Autonomic dysfunction  
-Prone to higher prevalence and 
severity of orthostatic symptoms 
-Higher rate of depression 
-Visual hallucinations 
-Increased frequency of falls 
-Impairment of colour vision  
 
Olfactory69 A. Severe loss of olfaction 
(anosmia)  
 
-dyskinesias 
-progressive weight loss 
 
 
 B. Moderate loss of olfaction -no further weight loss with 
disease progression 
Autonomic  Urinary dysfunction16 -early noradrenergic deficit  
-postural hypotension 
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Table 2:  Studies examining non-motor symptoms in motor subtypes and their timing of 
defining motor subtype. 
 
Author, year Mean Disease duration (SD) when 
motor subtype defined 
NMS associated with PIGD 
or AR motor subtype 
Rajput 200939 Multiple observations throughout 
course 
Cognitive dysfunction 
Aarsland 200340 9.2 (5.9) years 
 
Dementia (after prospective 
follow-up 
Muller 201136 2.3 (1.8) years 
Newly diagnosed, untreated 
Autonomic and sensory 
symptoms 
Reijnders 200923 Stavanger 9.0 (5.7) years 
Maastricht:  6.7 (5.0) years  
Single evaluation, variable disease 
duration 
 
Cognitive dysfunction, 
depression, apathy 
Stern 199441 Not reported. 
Single evaluation 
Olfactory disturbance 
Romenets 201261 Single evaluation variable disease 
duration 
With RBD 5.3 (3.9) 
Without RBD 6.3 (4.7) 
RBD 
Pont-Sunyer 201537 Median 11 months from motor 
symptom onset, 1 month from 
Constipation 
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diagnosis  
Single evaluation newly diagnosed 
untreated 
 
Khoo 201370 Median 4.4 months  
Single evaluation newly diagnosed 
untreated.  
Greater number of NMS, 
sialorrhea 
Herman 201438 PIGD: 5.7 ± 3.7 
Tremor dominant: 5.4 ± 3.2  
Single evaluation   
Autonomic symptoms 
(SCOPA-AUT) 
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Brainstem	dominant
(often	with
late	onset	hyposmia)
Sleep	dysfunction	(RBD/EDS)
Dysautonomia (Adrenergic)
Limbic	dominant
(often	with	anosmia)
Depression/Anxiety
Fatigue	(Sertonergic?)
Central	Pain	(Opioidergic?)
Weight	loss	
Cognitive	dominant
(late	onset	PD)
Amnestic MCI	(Cholinergic)
Apathy
Anxiety
Falls	with	cognitive	
impairment
Brainstem	route.	Ref		Braaket	al.		2003 Consequent	phenotype NMS	dominant	profile	(subtype)
Olfactory	to	limbic	.	Beach	et	al.	2009
Cognitive.	(Neocortical	subtype)	
Ref		Halliday et	al	2011/	Selikhova et	al.2009)
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